Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early-stage breast cancer. Here, we assessed the use of continuous metronomic weekly doxorubicin plus daily oral cyclophosphamide (AC) with continuous G-CSF growth factor support for 12 weeks followed by weekly nab-paclitaxel (nP) for 12 weeks. A nonrandomized phase II clinical trial was designed to assess (1) DFS at 2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities.
2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities.
The dosing of A was 24 mg/m2 IV weekly and C was 60 mg/m2 oral daily (with scheduled filgrastim 5mcg/kg 6 days/week); nP, 100 mg/m2 IV weekly. For patients with HER2 + disease, trastuzumab was started during the nP portion of therapy and continued for 12 months. Sixty patients enrolled with a median follow-up of 6 years. Node-positive disease was present in 58% of patients. Receptor categories included hormone receptor positive/HER2 negative (n = 25; 42%); triple negative (n = 19; 32%); or HER2 positive (n = 16; 27%). DFS at 2 years was 93%. Mean dose delivered was greater than 90% for metronomic AC and 88% for nP. Treatment was well tolerated with a 2% incidence of febrile neutropenia. Continuous metronomic AC followed by nP was well tolerated in our patients with comparable DFS to historical controls.
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| INTRODUCTION
Cytotoxic chemotherapy given after surgery for breast cancer results in decreasing recurrences in patients at high risk on the basis of biology or stage. 1 Chemotherapy regimens have evolved to increase intensity and density, both of which are maximized with better supportive care such as anti-emetics and granulocyte growth factors. 2 During the prior decade, a generally accepted standard of care option for high-risk early-stage patients was the regimen of every 2-week dose-dense doxorubicin plus cyclophosphamide for 4 cycles followed by paclitaxel delivered either every 2 weeks for 4 cycles or weekly for 12 cycles (ddAC 94 -> ddT 94 or wT 912).
In this report, we present data from a nonrandomized phase II clinical trial demonstrating tolerability and feasibly of continuous metronomic doxorubicin plus daily oral cyclophosphamide (AC) for 12 weeks with continuous G-CSF growth factor support followed by nab-paclitaxel (nP) for 12 weeks for high-risk early-stage breast cancer. This regimen represents an intended 20% greater intensity for doxorubicin and 40% for cyclophosphamide. nP is formulated to deliver drug without toxic carrier molecules and can be safely administered at higher doses than generally tolerated with conventional paclitaxel. The minimum dose intensity increase for the taxane in the current protocol compared with standard of care weekly dosing is 25%. We hypothesized that the regimen under study would compare favorably to standard of care from the prior decade in terms of toxicity profile, DFS, and OS for early-stage breast cancer.
| PATIENTS AND METHODS

| Study design and treatment
This single-arm phase II study included women who met one of the following criteria (1) ≥4 positive nodes, (2) 
| Patient population
Women with histologically confirmed breast carcinoma that had been surgically resected were eligible. HER2, ER, and PR were 
| Assessments and toxicity management
Validation of inclusion and exclusion criteria and a medical history were completed at baseline. Toxicity was assessed at each patient visit and for 30 days after the last dose. Follow-up was carried out every 3 months for 2 years, every 6 months for 2 years, and then annually. Laboratory work, imaging studies (as indicated), and assessments of health status occurred at these visits.
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (version 3). AC was held for absolute neutrophil count less than 1500 and/or platelet count less than 100 000. For neutropenia associated with AC, 25% dose reduction of both agents was initiated and continued through all subsequent cycles. nP was held for absolute neutrophil count less than 1000 and/or platelet count less than 75 000. For patients with fever >38 degrees with ANC <500, persistent neutropenia <500 for >1 week, or delay of next treatment due to persistent neutropenia, G-CSF was initiated with nP.
If neutropenia reoccurred despite G-CSF, nP dose was reduced to the À1 dose level (80 mg/m 2 ). For other grade 3 or 4 toxicities such as thrombocytopenia and peripheral neuropathy, nP was held and reduced at the next infusion to the À1 or À2 (65 mg/ m 2 ) dose level depending on the specific toxicity.
| Statistical methodology and analysis
The target enrollment was 60 patients to allow for drop out and assure 50 evaluable patients. contact. DFS and OS were assessed using the Kaplan-Meier method.
The analysis was conducted on the intent-to-treat population, which included all enrolled patients, and the safety analysis included all patients who received at least one dose of study drug. Table 1 shows baseline demographic characteristics. Of 60 enrolled patients, all 60 received AC but 4 patients received no nP due to early study discontinuation during the AC portion. Median follow-up was 6 years.
| RESULTS
Between
A total of 34 patients (57%) completed 12 weeks of AC and 12 weeks of nP. For all patients, the percent of planned doses administered of doxorubicin was 92.6% and cyclophosphamide was 92.1%.
The percent of planned doses administered of nP was 88.2% based on intent-to-treat and 92.9% when including only patients who still remained on study through at least one dose of nP. Of the 16 patients with HER2 positive disease, 15 patients remained on study through the nP portion and received trastuzumab as part of the study.
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| 611
All women with estrogen receptor-positive and/or progesterone receptor-positive disease were offered adjuvant endocrine therapy (Table 2) . One patient declined.
Of the 60 patients, 7 died. One patient was found to have metastatic (CNS) disease after 11 weeks of AC and was removed from the study. The median follow-up for living patients was 6 years, and during that period of time, there were 7 recurrences of breast cancer (2 local and 5 distant). Of the 7 patients who had a recurrence, 5 had stage III disease at time of diagnosis and 2 had stage II disease.
Four patients had ER/PR+ Her2-disease, two patients had triple negative disease, and 1 patient had ER/PR+ Her2+ ("triple positive") disease. Nonrecurrence DFS events included contralateral breast cancer (1), squamous cell carcinoma of unknown primary (1), and papillary thyroid cancer (1) ( Table 3) .
Kaplan-Meier (KM) curves and estimates were performed to show the OS and DFS, overall and by subgroups: (1) ER + and/or PR +, HER2À, (2) Her2+ patients, (3) triple negative ( Figure 1 and Table 4 ).
No statistically significant differences were observed between subgroups (P = .172 for OS and P = .715 for DFS, respectively).
The most common grade 3-4 adverse events were neutropenia, mucositis, hand-foot syndrome, and neuropathy (Table 5) 
| DISCUSSION
The addition of taxanes and optimization of the dosing schedule of anthracycline-based chemotherapy has improved outcomes in women with high-risk early-stage breast cancer. [2] [3] [4] Based on the reported efficacy of weekly paclitaxel 5, 6 and the benefit of nP seen in patients with metastatic breast cancer, 7 we elected to study nP in sequential combination with metronomic AC.
Although there were early signals of improved efficacy of more continuous dosing, 8 recent reporting of SWOG S0221 favored every 2-week dosing over continuous metronomic AC as used in our study. 4 This trial featured a randomization to 4 arms of treatment in a 2 9 2 design evaluating dose density with every week versus patients. DFS at 5 years was 81% overall and a log-rank test comparing all four arms simultaneously was not significant for the pri- | 613 routine use of the continuous AC regimen. In an unplanned subset analysis, there was a benefit in terms of overall survival for the group with triple negative breast cancer seen with the every 2-week regimen.
Interestingly, there was no benefit seen for DFS.
Our study showed excellent DFS of 93% at 2 years, which is very comparable to prior studies evaluating anthracycline followed by taxane sequencing. 5 At 6 years of follow-up, the DFS and OS are 82% and 88%, respectively. However, our small sample size limits ability to extrapolate these results to different subtypes and stage.
In addition, some of the benefit seen in HER2+ patients may be attributable to trastuzumab therapy.
This regimen of continuous metronomic doxorubicin with daily oral cyclophosphamide followed by weekly nP was well tolerated in our patients with a positive signal for efficacy. However, based on the results of S0221, a larger, randomized study, continuous metronomic AC may not be advisable over every 2-week AC. The substitution of weekly nP for paclitaxel may be of benefit in patients with infusion reactions or have poor tolerance of steroids due to comorbidities such as diabetes.
